ADMA Biologics, Inc. (ADMA) Stock Overview
Explore ADMA Biologics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
ADMA Biologics, Inc. (ADMA)
Key Financials
Key Financials
Market Cap
2.2B
P/E Ratio
13.19
EPS (TTM)
$0.71
ROE
0.40%
ADMA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of ADMA Biologics, Inc. (NASDAQ: ADMA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, ADMA Biologics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of ADMA on the NASDAQ shows an RSI of 54.57, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $7.01 for the NASDAQ listing.
Key metrics behind ADMA Biologics, Inc.'s NASDAQ-traded stock include a P/E ratio of 13.19 and a market capitalization of 2.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ADMA on the NASDAQ.